35 results on '"Bluhmki, Erich"'
Search Results
2. Alteplase for Acute Ischemic Stroke in Patients Aged >80 Years: Pooled Analyses of Individual Patient Data
3. Abstract 15893: Mediators of the Improvement in Heart Failure Outcomes With Empagliflozin in the EMPA-REG OUTCOME Trial
4. Corrigendum to “Reduced dose tenecteplase and outcomes in elderly ST-segment elevation myocardial infarction patients: Insights from the Strategic Reperfusion Early After Myocardial infarction trial” [Am Heart J 169/6 (2015) 890–898]
5. Effects of Alteplase for Acute Stroke on the Distribution of Functional Outcomes: A Pooled Analysis of 9 Trials
6. Online Tool to Improve Stratification of Adverse Events in Stroke Clinical Trials
7. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
8. Selection for delayed intravenous alteplase treatment based on a prognostic score
9. Thrombolysis for acute ischaemic stroke with alteplase in an Asian population: results of the multicenter, multinational Safe Implementation of Thrombolysis in Stroke-Non-European Union World (SITS-NEW)
10. Exploration of time-course combinations of outcome scales for use in a global test of stroke recovery
11. Fibrinolysis for Patients with Intermediate-Risk Pulmonary Embolism
12. Reduced dose tenecteplase and outcomes in elderly ST-segment elevation myocardial infarction patients: Insights from the STrategic Reperfusion Early After Myocardial infarction trial
13. Fibrinolysis or Primary PCI in ST-Segment Elevation Myocardial Infarction
14. Thrombolysis in Stroke Despite Contraindications or Warnings?
15. Influence of Age on Outcome From Thrombolysis in Acute Stroke: A Controlled Comparison in Patients From the Virtual International Stroke Trials Archive (VISTA)
16. The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study
17. Efficacy and Safety of Tissue Plasminogen Activator 3 to 4.5 Hours After Acute Ischemic Stroke: A Metaanalysis
18. Treatment Time-Specific Number Needed to Treat Estimates for Tissue Plasminogen Activator Therapy in Acute Stroke Based on Shifts Over the Entire Range of the Modified Rankin Scale
19. Thrombolysis during Resuscitation for Out-of-Hospital Cardiac Arrest
20. Multivariable Analysis of Outcome Predictors and Adjustment of Main Outcome Results to Baseline Data Profile in Randomized Controlled Trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST)
21. Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke
22. Predicting Long-Term Outcome After Acute Ischemic Stroke: A Simple Index Works in Patients From Controlled Clinical Trials
23. Shift Analysis Versus Dichotomization of the Modified Rankin Scale Outcome Scores in the NINDS and ECASS-II Trials
24. The Stroke–Thrombolytic Predictive Instrument: A Predictive Instrument for Intravenous Thrombolysis in Acute Ischemic Stroke
25. Can Multivariable Risk-Benefit Profiling Be Used to Select Treatment-Favorable Patients for Thrombolysis in Stroke in the 3- to 6-Hour Time Window?
26. Outcome and Symptomatic Bleeding Complications of Intravenous Thrombolysis Within 6 Hours in MRI-Selected Stroke Patients: Comparison of a German Multicenter Study With the Pooled Data of ATLANTIS, ECASS, and NINDS tPA Trials
27. Hemorrhagic Transformation of Ischemic Brain Tissue: Asymptomatic or Symptomatic?
28. Risk Factors for Severe Hemorrhagic Transformation in Ischemic Stroke Patients Treated With Recombinant Tissue Plasminogen Activator: A Secondary Analysis of the European-Australasian Acute Stroke Study (ECASS II)
29. Determination of a weight-adjusted dose of TNK–tissue plasminogen activator
30. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: The ASSENT-1 trial
31. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)
32. Dichotomized Efficacy End Points and Global End-Point Analysis Applied to the ECASS Intention-to-Treat Data Set: Post Hoc Analysis of ECASS I
33. The ECASS 3-Hour Cohort: Secondary Analysis of ECASS Data by Time Stratification
34. Hemorrhagic Transformation in Acute Ischemic Stroke: Potential Contributing Factors in the European Cooperative Acute Stroke Study
35. Intravenous Thrombolysis With Recombinant Tissue Plasminogen Activator for Acute Hemispheric Stroke: The European Cooperative Acute Stroke Study (ECASS)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.